Towards a more accessible and affordable healthcare system: regulate or innovate - by Aisling Burnand of the UK BIA
This article was originally published in Scrip
Reflecting on the past 35 years, we have seen a vast increase in the amount of money spent on healthcare in Britain. In 2005 the UK spent £109 billion on healthcare (8.3% of GDP) compared with a relatively minuscule 4.5% of GDP in 1970. The government’s 2007 comprehensive spending review (CSR) targeted an average real increase in NHS funding of 4% per year - to £110 billion a year by 2010-11, and a goal of increasing healthcare spending to between 10.5% and 11.5% of GDP.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.